Abstract
Patients with Stage I/II pelvic high-grade serous carcinoma (HGSC) have significant risk of recurrence and death. Although previous studies demonstrate overall survival benefit with intraperitoneal chemotherapy (IP) in Stage III disease, no studies have evaluated the outcomes in early stage disease. We offered IP chemotherapy (IP/IV) to patients with Stage I/II HGSC from 2009−2022. The objectives was to evaluate recurrence and overall survival in this cohort of patients, compared to those who received standard intravenous (IV) chemotherapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
